Dupilumab for cancer-associated refractory pruritus

BACKGROUND: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Descripción completa

Detalles Bibliográficos
Autores principales: Talmon, Aviv, Elias, Shlomo, Rubin, Limor, Ribak, Yaarit, Ben Dori, Eyal, Shamriz, Oded, Lotem, Michal, Adini, Irit, Tal, Yuval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509917/
https://www.ncbi.nlm.nih.gov/pubmed/37779518
http://dx.doi.org/10.1016/j.jacig.2023.100128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509917/
https://www.ncbi.nlm.nih.gov/pubmed/37779518
http://dx.doi.org/10.1016/j.jacig.2023.100128

Ejemplares similares